Capitalising on structurally growing life science and public IT spend. Divestment makes for a much more attractive earnings trajectory. 28% EPS CAGR in '24e-'27e not fully valued at 19x P/E: BUY.
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Author:
ABGSC IT Research | Mikkel Kousgaard Rasmussen
Pages:
43
Capitalising on structurally growing life science and public IT spend. Divestment makes for a much more attractive earnings trajectory. 28% EPS CAGR in '24e-'27e not fully valued at 19x P/E: BUY.
